Comparison of twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents

被引：0
|
作者：
Raskin, P
Rojas, P
Allen, E
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A143 / A143
页数：1
相关论文
共 50 条
  • [21] Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin aspart 70/30 before supper
    Jain, R
    Wahl, T
    Wahlen, J
    Bressler, P
    Hu, P
    Allen, E
    DIABETES, 2004, 53 : A130 - A130
  • [22] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
    Naiker, P.
    Makan, H. A.
    Omar, M. A. K.
    Kedijang, T.
    Kong, L. L. L.
    DIABETOLOGIA, 2006, 49 : 599 - 600
  • [23] Comparison of the cost to reach A1C targets in patients with type-2 diabetes mellitus on oral antidiabetic agents and either biphasic insulin aspart 70/30 or insulin glargine
    Cobden, D
    Allen, E
    Botteman, M
    VALUE IN HEALTH, 2005, 8 (03) : 358 - 358
  • [24] Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin
    Chen, Xi
    Xu, Yongping
    Zhang, Jianhua
    Shao, Shiyin
    Duan, Yanran
    Liu, Peiwen
    Shen, Liya
    Zhang, Jing
    Zeng, Jiaoe
    Lin, Mei
    Zhao, Shi
    Ma, Jianhua
    Zhao, Tao
    Hu, Juping
    Liao, Yong
    Chen, Xiaowen
    Hu, Shufang
    Xue, Yaoming
    Zeng, Zhaoyang
    He, Wentao
    Liu, Zhelong
    Li, Wenjun
    Liu, Liegang
    Yin, Ping
    Yu, Xuefeng
    ENDOCRINE PRACTICE, 2021, 27 (08) : 790 - 797
  • [25] Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
    Yang, Wenying
    Ersoy, Canan
    Wang, Guixia
    Ye, Shandong
    Liu, Jun
    Miao, Heng
    Asirvatham, Arthur
    Werther, Shanti
    Kadu, Priti
    Chow, Francis
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 158 - 166
  • [26] Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT
    Strojek, Krzysztof
    Bebakar, Wan M. W.
    Khutsoane, Duma T.
    Pesic, Milica
    Smahelova, Alena
    Thomsen, Henrik F.
    Kalra, Sanjay
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2887 - 2894
  • [27] A thrice-daily regimen of BIAsp 70 improves glycaemic control without increasing the risk of hypoglycaemia in Japanese patients with type 2 diabetes: a comparison of thrice-daily BIAsp 70 and twice-daily BIAsp 30
    Kadowaki, T.
    Kanai, M.
    Katayama, Y.
    Kaku, K.
    DIABETOLOGIA, 2008, 51 : S402 - S403
  • [28] Once-Daily Initiation with NovoMix® 30 (BIAsp 30) vs Insulin Glargine in Patients with Type 2 Diabetes Inadequately Controlled with Oral Drugs: A Randomized Controlled Trial
    Strojek, Krzysztof
    Bebakar, Wan M. W.
    Khutsoane, Duma T.
    Pesic, Milica
    Smahelova, Alena
    Thomsen, Henrik F.
    Kalra, Sanjay
    DIABETES, 2009, 58 : A146 - A146
  • [29] Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus
    McSorley, PT
    Bell, PM
    Jacobsen, LV
    Kristensen, A
    Lindholm, A
    CLINICAL THERAPEUTICS, 2002, 24 (04) : 530 - 539
  • [30] Efficacy of biphasic insulin aspart 70/30 in insulin-naive patients with type 2 diabetes mellitus not achieving glycemic targets on oral antidiabetic agents
    Garber, Alan J.
    Jain, Rajeev
    Wahl, Timothy
    Moses, Alan
    Cao, Anjun
    Bressler, Peter
    DIABETES, 2006, 55 : A477 - A477
12345